BioClinica offers streamlined electronic transport solutions with the acquisition of CardioNow

BioClinica, Inc., (NASDAQ: BIOC), a global provider of clinical trial services, today announced that it has acquired the CardioNow unit of Agfa HealthCare. With this addition, BioClinica now offers streamlined electronic transport solutions to facilitate the blinding, sharing, tracking and archiving of medical images for multi-center clinical trials as part of its suite of imaging services. Imaging information will also be integrated with BioClinica Express electronic data capture to further simplify and enhance the clinical trial process for life science companies.

Since 1999, CardioNow has provided core labs, investigator sites, and medical device and pharmaceutical companies with an established and proven web-based system for the secure, regulatory compliant transmission and analysis of medical images that are integral components of clinical trials. The solution is also extensively utilized by remote independent reviewers for online case review and quantitative analysis, clinical event adjudication, and data safety monitoring. Over the past 10 years, CardioNow has successfully managed more than 8.8 million DICOM (Digital Imaging and Communications in Medicine) images for clinical studies worldwide.

With the integration of CardioNow, BioClinica will be able to manage every step of the process that begins once a medical image is acquired at a clinical site through the delivery of evaluated results to the sponsor. This end-to-end control will ensure that the process is as efficient and expedient as possible.

“CardioNow fits perfectly into BioClinica’s strategy of adding components that are both complimentary to our current products and services and that help to create a more efficient clinical trial process. We will continue to build on the superior technology and high level of customer service offered by Agfa Healthcare’s CardioNow unit,” said Mark Weinstein, President and CEO of BioClinica. “An additional benefit is that once CardioNow is integrated with our current processes -- approximately 45 days -- we can offer our clients an immediate cost savings on each of the more than 200 clinical trials that we are currently supporting.”

“A leading solution like CardioNow is well suited to support the ongoing expansion of BioClinica’s extensive global clinical trial services portfolio,” said Eric Maurincomme, Chief Strategy & Marketing Officer of Agfa HealthCare. “We are convinced that the CardioNow business will continue to flourish within BioClinica, and are working closely together to enable a smooth transition.”

Mr. Weinstein concluded, “CardioNow will provide immediate benefits to our Bioimaging Services clients and as such the CardioNow team will be integrated into that division and report to Dave Pitler, president of our Bio-Imaging Services division. We will immediately begin work on integrating the CardioNow products and services with our eclinical offering to provide medical device and pharmaceutical clients with a comprehensive offering that will be unmatched in the industry.”